-
WHO grants emergency usage listing for Covaxin
Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant
-
SGX Nifty: Key things to know before stock market opening
Wall Street stocks surged to a higher close on Friday boosted by positive economic data.
-
Key factors that will guide markets next week
On the coronavirus front, investors would continuously watch out government's course of action along with progress on the vaccination drive.
-
Key factors that will guide markets next week
Auto stocks will be in focus as auto companies will start announcing monthly sales numbers for September starting from 1 October 2021.
-
Close to 85 crore Covid vaccines administered country-wise
In terms of aggregate number, UP tops the char at nearly 10 crore
-
Record IPOs, market tops: Will it lead to the market crash?
In 2021 to date, 38 new IPOs have hit the market and another 20-25 are scheduled to make their debut.
-
COVAX cuts delivery target by 25% due to supply constraints
As per the latest supply forecast, 1.1 billion doses are expected to become available for delivery between September and the end of 2021
-
SGX Nifty indicates a negative opening for Indian indices
Key equity indices BSE Sensex and NSE Nifty ended flat after a volatile trade on Wednesday, tracking negative global cues.
-
Antibody therapy from AstraZeneca prevents Covid-19: Study
AstraZeneca has become the first company to publish positive Covid prevention data from an antibody trial
-
Chris Wood raises weightage on Indian equities
The major risk to GREED & fear is the arrival of a new Covid variant. But that is a risk shared with the rest of the world.
